Dataset from ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S)
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008333
下载链接
链接失效反馈官方服务：
资源简介：
This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the
efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib
in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal
growth factor receptor EGFR-activating mutation (s). Analyses of primary objective
(Progression Free Survival) will be done as defined in the protocol.
创建时间：
2025-07-07
